Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Modified sites and functional consequences of 4-oxo-2-nonenal adducts in HDL that are elevated in familial hypercholesterolemia.

May-Zhang LS, Yermalitsky V, Melchior JT, Morris J, Tallman KA, Borja MS, Pleasent T, Amarnath V, Song W, Yancey PG, Davidson WS, Linton MF, Davies SS.

J Biol Chem. 2019 Oct 30. pii: jbc.RA119.009424. doi: 10.1074/jbc.RA119.009424. [Epub ahead of print]

2.

Lipoprotein modulation of proteinuric renal injury.

Tsuchida Y, Zhong J, Otsuka T, Dikalova A, Pastan I, Anantharamaiah GM, Linton MF, Yancey PG, Ikizler TA, Fogo AB, Yang H, Kon V.

Lab Invest. 2019 Jul;99(8):1107-1116. doi: 10.1038/s41374-019-0253-6. Epub 2019 Apr 24.

3.

IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD.

Hung AM, Tsuchida Y, Nowak KL, Sarkar S, Chonchol M, Whitfield V, Salas N, Dikalova A, Yancey PG, Huang J, Linton MF, Ikizler TA, Kon V.

Clin J Am Soc Nephrol. 2019 May 7;14(5):702-711. doi: 10.2215/CJN.04360418. Epub 2019 Apr 23.

PMID:
31015261
4.

Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor-/- Mice Improves Indices of Cardiometabolic Disease.

May-Zhang LS, Chen Z, Dosoky NS, Yancey PG, Boyd KL, Hasty AH, Linton MF, Davies SS.

Sci Rep. 2019 Jan 23;9(1):420. doi: 10.1038/s41598-018-37373-1.

5.

Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation.

Brophy ML, Dong Y, Tao H, Yancey PG, Song K, Zhang K, Wen A, Wu H, Lee Y, Malovichko MV, Sithu SD, Wong S, Yu L, Kocher O, Bischoff J, Srivastava S, Linton MF, Ley K, Chen H.

Circ Res. 2019 Feb 15;124(4):e6-e19. doi: 10.1161/CIRCRESAHA.118.313028.

PMID:
30595089
6.

Modification by isolevuglandins, highly reactive γ-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function.

May-Zhang LS, Yermalitsky V, Huang J, Pleasent T, Borja MS, Oda MN, Jerome WG, Yancey PG, Linton MF, Davies SS.

J Biol Chem. 2018 Jun 15;293(24):9176-9187. doi: 10.1074/jbc.RA117.001099. Epub 2018 Apr 30.

7.

Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism.

Kaseda R, Tsuchida Y, Yang HC, Yancey PG, Zhong J, Tao H, Bian A, Fogo AB, Linton MRF, Fazio S, Ikizler TA, Kon V.

BMC Nephrol. 2018 Jan 27;19(1):17. doi: 10.1186/s12882-018-0814-8.

8.

SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis.

Linton MF, Tao H, Linton EF, Yancey PG.

Trends Endocrinol Metab. 2017 Jun;28(6):461-472. doi: 10.1016/j.tem.2017.02.001. Epub 2017 Mar 1. Review.

9.

Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis.

Ormseth MJ, Yancey PG, Yamamoto S, Oeser AM, Gebretsadik T, Shintani A, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Raggi P, Kon V, Stein CM.

IJC Metab Endocr. 2016 Dec;13:6-11. doi: 10.1016/j.ijcme.2016.08.002. Epub 2016 Aug 28.

10.

Macrophage Apoptosis and Efferocytosis in the Pathogenesis of Atherosclerosis.

Linton MF, Babaev VR, Huang J, Linton EF, Tao H, Yancey PG.

Circ J. 2016 Oct 25;80(11):2259-2268. Epub 2016 Oct 8. Review.

11.

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.

Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C; TETRAD Investigators.

Arthritis Rheumatol. 2016 Sep;68(9):2099-105. doi: 10.1002/art.39675.

12.

The Role of Lipids and Lipoproteins in Atherosclerosis.

Linton MRF, Yancey PG, Davies SS, Jerome WG, Linton EF, Song WL, Doran AC, Vickers KC.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2019 Jan 3.

13.

Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V.

Atherosclerosis. 2015 Sep;242(1):56-64. doi: 10.1016/j.atherosclerosis.2015.06.055. Epub 2015 Jul 4.

14.

Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis.

Tao H, Yancey PG, Babaev VR, Blakemore JL, Zhang Y, Ding L, Fazio S, Linton MF.

J Lipid Res. 2015 Aug;56(8):1449-60. doi: 10.1194/jlr.M056689. Epub 2015 Jun 9.

15.

Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts.

Guo L, Chen Z, Amarnath V, Yancey PG, Van Lenten BJ, Savage JR, Fazio S, Linton MF, Davies SS.

Antioxid Redox Signal. 2015 Jun 20;22(18):1633-45. doi: 10.1089/ars.2014.6078. Epub 2015 Mar 18.

16.

Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL.

Tavori H, Su YR, Yancey PG, Giunzioni I, Wilhelm AJ, Blakemore JL, Zabalawi M, Linton MF, Sorci-Thomas MG, Fazio S.

J Lipid Res. 2015 Mar;56(3):635-43. doi: 10.1194/jlr.M056408. Epub 2015 Jan 15.

17.

Dysfunctional high-density lipoproteins in children with chronic kidney disease.

Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V.

Metabolism. 2015 Feb;64(2):263-73. doi: 10.1016/j.metabol.2014.10.020. Epub 2014 Oct 25.

18.

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.

Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20.

19.

Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.

Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V.

J Am Coll Cardiol. 2012 Dec 11;60(23):2372-9. doi: 10.1016/j.jacc.2012.09.013. Epub 2012 Nov 7.

20.

Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.

Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2856-64. doi: 10.1161/ATVBAHA.111.237198. Epub 2011 Oct 6.

21.

Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent.

Yancey PG, Ding Y, Fan D, Blakemore JL, Zhang Y, Ding L, Zhang J, Linton MF, Fazio S.

Circulation. 2011 Jul 26;124(4):454-64. doi: 10.1161/CIRCULATIONAHA.111.032268. Epub 2011 Jul 5.

22.

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.

Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, Fogo AB, Linton MF, Fazio S, Ichikawa I, Kon V.

Nephrol Dial Transplant. 2011 Aug;26(8):2491-7. doi: 10.1093/ndt/gfq759. Epub 2011 Jan 18.

23.

Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation.

Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF, Fazio S.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):787-95. doi: 10.1161/ATVBAHA.109.202051. Epub 2010 Feb 11.

24.

Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.

Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I.

J Lipid Res. 2008 May;49(5):1015-23. doi: 10.1194/jlr.M700535-JLR200. Epub 2008 Feb 2.

25.

Self-association of human PCSK9 correlates with its LDLR-degrading activity.

Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ, Linton MF, Fazio S.

Biochemistry. 2008 Feb 12;47(6):1631-9. doi: 10.1021/bi7016359. Epub 2008 Jan 16.

26.

Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.

Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, Semenkovich CF, Fazio S, Linton MF.

Circulation. 2007 Sep 18;116(12):1404-12. Epub 2007 Aug 27.

PMID:
17724261
27.

Impaired secretion of apolipoprotein E2 from macrophages.

Fan D, Qiu S, Overton CD, Yancey PG, Swift LL, Jerome WG, Linton MF, Fazio S.

J Biol Chem. 2007 May 4;282(18):13746-53. Epub 2007 Mar 6.

28.

A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells.

Yancey PG, Yu H, Linton MF, Fazio S.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1123-31. Epub 2007 Feb 15.

PMID:
17303773
29.

Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse.

Overton CD, Yancey PG, Major AS, Linton MF, Fazio S.

Circ Res. 2007 Mar 16;100(5):670-7. Epub 2007 Feb 15.

PMID:
17303763
30.

Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI.

Yancey PG, Jerome WG, Yu H, Griffin EE, Cox BE, Babaev VR, Fazio S, Linton MF.

J Lipid Res. 2007 May;48(5):1140-9. Epub 2007 Feb 13.

31.

Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells.

Braun NA, Mohler PJ, Weisgraber KH, Hasty AH, Linton MF, Yancey PG, Su YR, Fazio S, Swift LL.

J Lipid Res. 2006 Jun;47(6):1176-86. Epub 2006 Mar 13.

32.

Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice.

Yu H, Zhang W, Yancey PG, Koury MJ, Zhang Y, Fazio S, Linton MF.

Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):150-6. Epub 2005 Nov 3.

PMID:
16269665
33.

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.

Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF.

J Mol Cell Cardiol. 2005 Sep;39(3):443-52.

PMID:
16040051
34.

Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.

Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1647-53. Epub 2005 Jun 9.

PMID:
15947238
35.

SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients with Alagille syndrome.

Yancey PG, Asztalos BF, Stettler N, Piccoli D, Williams DL, Connelly MA, Rothblat GH.

J Lipid Res. 2004 Sep;45(9):1724-32. Epub 2004 Jun 21.

36.

In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux.

Yancey PG, Kawashiri MA, Moore R, Glick JM, Williams DL, Connelly MA, Rader DJ, Rothblat GH.

J Lipid Res. 2004 Feb;45(2):337-46. Epub 2003 Nov 1.

37.

Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice.

Zhang W, Yancey PG, Su YR, Babaev VR, Zhang Y, Fazio S, Linton MF.

Circulation. 2003 Nov 4;108(18):2258-63. Epub 2003 Oct 27.

PMID:
14581413
38.

Testing the role of apoA-I, HDL, and cholesterol efflux in the atheroprotective action of low-level apoE expression.

Thorngate FE, Yancey PG, Kellner-Weibel G, Rudel LL, Rothblat GH, Williams DL.

J Lipid Res. 2003 Dec;44(12):2331-8. Epub 2003 Sep 1.

39.

Importance of different pathways of cellular cholesterol efflux.

Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH.

Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):712-9. Epub 2003 Jan 23. Review.

PMID:
12615688
40.

The role of microscopy in understanding atherosclerotic lysosomal lipid metabolism.

Jerome WG, Yancey PG.

Microsc Microanal. 2003 Feb;9(1):54-67. Review.

PMID:
12597787
41.
42.

Cellular cholesterol flux studies: methodological considerations.

Rothblat GH, de la Llera-Moya M, Favari E, Yancey PG, Kellner-Weibel G.

Atherosclerosis. 2002 Jul;163(1):1-8.

PMID:
12048116
43.

Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL.

de La Llera-Moya M, Connelly MA, Drazul D, Klein SM, Favari E, Yancey PG, Williams DL, Rothblat GH.

J Lipid Res. 2001 Dec;42(12):1969-78.

44.

Analysis of chimeric receptors shows that multiple distinct functional activities of scavenger receptor, class B, type I (SR-BI), are localized to the extracellular receptor domain.

Connelly MA, de la Llera-Moya M, Monzo P, Yancey PG, Drazul D, Stoudt G, Fournier N, Klein SM, Rothblat GH, Williams DL.

Biochemistry. 2001 May 1;40(17):5249-59.

PMID:
11318648
45.
46.

High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI.

Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH.

J Biol Chem. 2000 Nov 24;275(47):36596-604.

47.

Crystallization of free cholesterol in model macrophage foam cells.

Kellner-Weibel G, Yancey PG, Jerome WG, Walser T, Mason RP, Phillips MC, Rothblat GH.

Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1891-8.

PMID:
10446067
48.
50.

Cellular cholesterol efflux mediated by cyclodextrins. Demonstration Of kinetic pools and mechanism of efflux.

Yancey PG, Rodrigueza WV, Kilsdonk EP, Stoudt GW, Johnson WJ, Phillips MC, Rothblat GH.

J Biol Chem. 1996 Jul 5;271(27):16026-34.

Supplemental Content

Loading ...
Support Center